Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

Charles E. Grimshaw; Andy Jennings; Ruhi Kamran; Hikaru Ueno; Nobuhiro Nishigaki; Takuo Kosaka; Akiyoshi Tani; Hiroki Sano; Yoshinobu Kinugawa; Emiko Koumura; Lihong Shi; Koji Takeuchi

doi:10.1371/journal.pone.0157509

Loading metrics

Open Access

Peer-reviewed

Research Article

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

Charles E. Grimshaw ,

* E-mail: ched.grimshaw@takeda.com

Affiliation Enzymology and Biophysical Chemistry, Takeda California, Inc., San Diego, California, United States of America

http://orcid.org/0000-0002-2897-3483

⨯
Andy Jennings,

Affiliation Computational Sciences and Crystallography, Takeda California, Inc., San Diego, California, United States of America
⨯
Ruhi Kamran,

Affiliation Enzymology and Biophysical Chemistry, Takeda California, Inc., San Diego, California, United States of America
⨯
Hikaru Ueno,

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Nobuhiro Nishigaki,

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Takuo Kosaka,

Affiliation Bio-Molecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Akiyoshi Tani,

Affiliation Bio-Molecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯
Hiroki Sano,

Affiliation Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
⨯
Yoshinobu Kinugawa,

Affiliation Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
⨯
Emiko Koumura,

Affiliation Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan
⨯
Lihong Shi,

Current address: Celgene Quanticel Research, San Diego, California, United States of America

Affiliation Enzymology and Biophysical Chemistry, Takeda California, Inc., San Diego, California, United States of America
⨯
Koji Takeuchi

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
⨯

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

Charles E. Grimshaw,
Andy Jennings,
Ruhi Kamran,
Hikaru Ueno,
Nobuhiro Nishigaki,
Takuo Kosaka,
Akiyoshi Tani,
Hiroki Sano,
Yoshinobu Kinugawa,
Emiko Koumura

Published: June 21, 2016
https://doi.org/10.1371/journal.pone.0157509

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Blood plasma
Is the Subject Area "Blood plasma" applicable to this article?

Thanks for your feedback.
Crystal structure
Is the Subject Area "Crystal structure" applicable to this article?

Thanks for your feedback.
Dogs
Is the Subject Area "Dogs" applicable to this article?

Thanks for your feedback.
Type 2 diabetes
Is the Subject Area "Type 2 diabetes" applicable to this article?

Thanks for your feedback.
Chemical dissociation
Is the Subject Area "Chemical dissociation" applicable to this article?

Thanks for your feedback.
Diabetes mellitus
Is the Subject Area "Diabetes mellitus" applicable to this article?

Thanks for your feedback.
Proteases
Is the Subject Area "Proteases" applicable to this article?

Thanks for your feedback.
Enzyme inhibitors
Is the Subject Area "Enzyme inhibitors" applicable to this article?

Thanks for your feedback.